Biologics Market:Â Monoclonal Antibodies to Emerge as Most Lucrative Product Segment
The Biologics Market is expected to grow at an impressive pace during the forecast period. The gains will be driven by substantial investments in research and developmental activities in the biotechnology and pharmaceutical sector and the soaring demand for novel therapies for various rare diseases. Recent intensive researches in novel therapies and combination therapies have established the efficacy of biologics for treating a wide range of chronic diseases such as cancer, rheumatoid arthritis, macular degeneration, and hematological malignancies. The introduction...
View full press release